Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia
Nema prikaza
Autori
Cvetković, MirjanaŽivković, Maja
Bundalo, Maja M.
Gojković, Ivana
Spasojević-Dimitrijeva, Brankica
Stanković, Aleksandra
Kostić, Mirjana M.
Članak u časopisu (Objavljena verzija)
,
© 2017 Wolters Kluwer Health, Inc
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily. Altered CYP3A enzyme activity was associated with variant allele of P450 oxidoreductase gene (POR*28). The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients. Methods: Renal transplant patients receiving CsA (n = 47) were genotyped for CYP3A5*3, CYP3A4*22, and POR*28. Results: CYP3A5 nonexpressers had higher overall dose-adjusted predose concentration (C0/dose; ng/mL per mg/kg) compared with expressers (31.48 +/- 12.75 versus 22.44 +/- 7.12, P = 0.01). CY-P3A5 nonexpressers carrying POR*28 allele had a lower overall dose-adjusted concentration (C2/dose) than those with POR*1/*1 genotype (165.54 +/- 70.40 versus 210.55 +/- 79.98, P = 0.02), with age as covariate. Children aged 6 years and younger had a lower overall C0/do...se (18.82 +/- 4.72 versus 34.19 +/- 11.89, P = 0.001) and C2/dose (106.75 +/- 26.99 versus 209.20 +/- 71.57, P LT 0.001) compared with older children. Carriers of CYP3A5*3 allele aged LT = 6 years required higher dose of CsA and achieved lower C0/dose and C2/dose, at most time points, than older carriers of this allele. Carriers of POR*28 allele aged # 6 years required higher doses of CsA, whereas they achieved lower C0/dose and C2/dose, at most time points, in comparison to older carriers of this allele. The significant effect of age (P LT 0.002) and CYP3A5 variation (P, 0.02) was shown for overall C0/dose, whereas age (P LT 0.00001) and POR variation (P = 0.05) showed significant effect on C2/dose. Regression summary for overall C2/dose in patients aged 6 years younger showed a significant effect of both CYP3A5 and POR variations (P LT 0.016). Conclusions: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio. Pretransplant screening of relevant polymorphisms in accordance with age should be considered to adjust therapy.
Ključne reči:
CYP3A / POR*28 / cyclosporin / kidney transplantation / pediatricIzvor:
Therapeutic Drug Monitoring, 2017, 39, 6, 589-595Finansiranje / projekti:
DOI: 10.1097/FTD.0000000000000442
ISSN: 0163-4356
PubMed: 29135906
WoS: 000423029800003
Scopus: 2-s2.0-85045636376
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Cvetković, Mirjana AU - Živković, Maja AU - Bundalo, Maja M. AU - Gojković, Ivana AU - Spasojević-Dimitrijeva, Brankica AU - Stanković, Aleksandra AU - Kostić, Mirjana M. PY - 2017 UR - https://vinar.vin.bg.ac.rs/handle/123456789/1918 AB - Background: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily. Altered CYP3A enzyme activity was associated with variant allele of P450 oxidoreductase gene (POR*28). The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients. Methods: Renal transplant patients receiving CsA (n = 47) were genotyped for CYP3A5*3, CYP3A4*22, and POR*28. Results: CYP3A5 nonexpressers had higher overall dose-adjusted predose concentration (C0/dose; ng/mL per mg/kg) compared with expressers (31.48 +/- 12.75 versus 22.44 +/- 7.12, P = 0.01). CY-P3A5 nonexpressers carrying POR*28 allele had a lower overall dose-adjusted concentration (C2/dose) than those with POR*1/*1 genotype (165.54 +/- 70.40 versus 210.55 +/- 79.98, P = 0.02), with age as covariate. Children aged 6 years and younger had a lower overall C0/dose (18.82 +/- 4.72 versus 34.19 +/- 11.89, P = 0.001) and C2/dose (106.75 +/- 26.99 versus 209.20 +/- 71.57, P LT 0.001) compared with older children. Carriers of CYP3A5*3 allele aged LT = 6 years required higher dose of CsA and achieved lower C0/dose and C2/dose, at most time points, than older carriers of this allele. Carriers of POR*28 allele aged # 6 years required higher doses of CsA, whereas they achieved lower C0/dose and C2/dose, at most time points, in comparison to older carriers of this allele. The significant effect of age (P LT 0.002) and CYP3A5 variation (P, 0.02) was shown for overall C0/dose, whereas age (P LT 0.00001) and POR variation (P = 0.05) showed significant effect on C2/dose. Regression summary for overall C2/dose in patients aged 6 years younger showed a significant effect of both CYP3A5 and POR variations (P LT 0.016). Conclusions: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio. Pretransplant screening of relevant polymorphisms in accordance with age should be considered to adjust therapy. T2 - Therapeutic Drug Monitoring T1 - Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia VL - 39 IS - 6 SP - 589 EP - 595 DO - 10.1097/FTD.0000000000000442 ER -
@article{ author = "Cvetković, Mirjana and Živković, Maja and Bundalo, Maja M. and Gojković, Ivana and Spasojević-Dimitrijeva, Brankica and Stanković, Aleksandra and Kostić, Mirjana M.", year = "2017", abstract = "Background: The interindividual variability of cyclosporin A (CsA) pharmacokinetics might be explained by heterogeneity in the cytochrome P450 3A (CYP3A) subfamily. Altered CYP3A enzyme activity was associated with variant allele of P450 oxidoreductase gene (POR*28). The aim of this study was to assess the impact of age, CYP3A5*3, CYP3A4*22, and POR*28 alleles on CsA pharmacokinetics in pediatric renal transplant recipients. Methods: Renal transplant patients receiving CsA (n = 47) were genotyped for CYP3A5*3, CYP3A4*22, and POR*28. Results: CYP3A5 nonexpressers had higher overall dose-adjusted predose concentration (C0/dose; ng/mL per mg/kg) compared with expressers (31.48 +/- 12.75 versus 22.44 +/- 7.12, P = 0.01). CY-P3A5 nonexpressers carrying POR*28 allele had a lower overall dose-adjusted concentration (C2/dose) than those with POR*1/*1 genotype (165.54 +/- 70.40 versus 210.55 +/- 79.98, P = 0.02), with age as covariate. Children aged 6 years and younger had a lower overall C0/dose (18.82 +/- 4.72 versus 34.19 +/- 11.89, P = 0.001) and C2/dose (106.75 +/- 26.99 versus 209.20 +/- 71.57, P LT 0.001) compared with older children. Carriers of CYP3A5*3 allele aged LT = 6 years required higher dose of CsA and achieved lower C0/dose and C2/dose, at most time points, than older carriers of this allele. Carriers of POR*28 allele aged # 6 years required higher doses of CsA, whereas they achieved lower C0/dose and C2/dose, at most time points, in comparison to older carriers of this allele. The significant effect of age (P LT 0.002) and CYP3A5 variation (P, 0.02) was shown for overall C0/dose, whereas age (P LT 0.00001) and POR variation (P = 0.05) showed significant effect on C2/dose. Regression summary for overall C2/dose in patients aged 6 years younger showed a significant effect of both CYP3A5 and POR variations (P LT 0.016). Conclusions: Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher CsA dosing requirements and lower concentration/dose ratio. Pretransplant screening of relevant polymorphisms in accordance with age should be considered to adjust therapy.", journal = "Therapeutic Drug Monitoring", title = "Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia", volume = "39", number = "6", pages = "589-595", doi = "10.1097/FTD.0000000000000442" }
Cvetković, M., Živković, M., Bundalo, M. M., Gojković, I., Spasojević-Dimitrijeva, B., Stanković, A.,& Kostić, M. M.. (2017). Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. in Therapeutic Drug Monitoring, 39(6), 589-595. https://doi.org/10.1097/FTD.0000000000000442
Cvetković M, Živković M, Bundalo MM, Gojković I, Spasojević-Dimitrijeva B, Stanković A, Kostić MM. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. in Therapeutic Drug Monitoring. 2017;39(6):589-595. doi:10.1097/FTD.0000000000000442 .
Cvetković, Mirjana, Živković, Maja, Bundalo, Maja M., Gojković, Ivana, Spasojević-Dimitrijeva, Brankica, Stanković, Aleksandra, Kostić, Mirjana M., "Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia" in Therapeutic Drug Monitoring, 39, no. 6 (2017):589-595, https://doi.org/10.1097/FTD.0000000000000442 . .